Group items tagged

The purpose of this funding is to support etiologic and effectiveness research on driving while polysubstance impaired. Specifically, research is solicited to identify risk and protective factors associated with polysubstance impaired driving and its associated deaths and injuries, or to identify effective interventions to prevent polysubstance impaired driving and its associated deaths and injuries. Polysubstance impaired driving includes driving while impaired by alcohol plus at least one other drug, such as marijuana or opioids. Research Priority #1 is to conduct etiologic research to inform our understanding of the characteristics of and risk and protective factors associated with impaired driving when alcohol plus other drugs (such as marijuana or prescription or illicit opioids) are involved. Research Priority #2 is to conduct effectiveness research to evaluate interventions most effective at preventing driving while impaired by alcohol plus other drugs (such as marijuana or prescription or illicit opioids).

The Biomedical Advanced Research and Development Authority (BARDA), Division of Research, Innovation and Ventures (DRIVe) is releasing this ÂœDRIVe Accelerator Network Funding Opportunity Announcement (FOA) to solicit applicants interested in working with BARDA DRIVe to stimulate the public good by creating or leveraging a network of accelerators across America to promote national health security innovation. In order to address the serious 21st century health threats facing our nation, BARDA DRIVe invests in innovative products (therapies, vaccines, diagnostics, and devices), technologies and tools in order to increase our capability and capacity to respond. Collectively, these will be referred to as health security products and technologies. Applicants who enter agreements with BARDA will become members of the Accelerator Network to: Support BARDA DRIVe health security products and technologies as they navigate research, development, and regulatory pathways; Provide wrap-around services to assist the R&D efforts (such as technical and business advice, access to facilities and incubator spaces, integration services);

This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be imbedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems.

This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, prevent suicide attempts (nonfatal and fatal), and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be imbedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems.

The Investigator-Initiated Translational Research Award (IITRA) supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following: * Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts. * Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission. * Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

The mission of BTO is to leverage biology as a technology to solve intractable problems. BTO seeks to leverage advances in engineering and computer science to drive and reshape biotechnology for national security. To achieve this vision, BTO is interested in a range of emerging technical areas, including but not limited to human-machine interfaces, human performance, infectious disease, and synthetic biology. The overarching goal is to develop, demonstrate, and transition biologically-based technologies as part of the national security toolkit.

The National Multiple Sclerosis Society mobilizes people and resources to drive research for a cure and to address the challenges of people affected by MS. To that end, the society is accepting applications for its Pilot Grant Program, which provides high-risk pilot grants for the testing of novel ideas that may serve to advance its mission of stopping MS progression, restoring function, improving quality of life, and preventing MS. The program supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care, and rehabilitation.

The Foundation Fighting Blindness (FFB) is soliciting applications for Career Development Awards (CDA) from clinical research scientists of superior dedication and talent. The award is for junior investigators to pursue vigorous research programs to drive the research to find the  therapies and cures for retinal degenerative diseases (RDDs), i.e., inherited orphan retinal degenerative diseases and non-exudative age-related macular degeneration. The goal of this Program is to facilitate advances in laboratory and clinical research, to elucidate the mechanisms for the etiology and pathogenesis of RDDs and to develop innovative strategies to prevent, treat and cure these diseases. 

The purpose of this Funding Opportunity Announcement (FOA)is to encourage research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which we do not have a strong understanding of the genetics/genomics of the disease or disorder. Applicable areas of investigation include identification of promising areas of the genome, and characterization and elucidation of the function(s) of genetic variants that affect disease risk in humans. The ultimate goal of these studies will be to drive development of effective diagnostic, therapeutic, and preventive approaches.

The mission of the Simons Foundation Autism Research Initiative  is to improve the diagnosis and treatment of autism spectrum disorders through the funding, catalyzing, and driving of high-quality research. To that end, the program is seeking applications for SFARI awards from individuals eager to conduct bold, imaginative, rigorous, and relevant research.

The current FOA aims to support HIV preventive interventions in Mozambique targeting KP and OVP in provinces of Mozambique characterized by high prevalence of HIV, rapid development and increasing number of multinational companies, transport corridor areas, high mobility and transient male workforce, increased tourism, and increased HIV risk from commercial sex work and transactional sex, which together constitute some of the main factors driving the epidemic in Mozambique. A successful FOA respondent will support the adoption of combination prevention approaches targeting behavioral, biomedical, and structural interventions to ensure effective reach and impact on target population. Interventions aim to increase knowledge of HIV and sexually transmitted infections (STIs) among KP and other priority populations, reduce sexual risk behavior, increase knowledge and access to preventive commodities among target population. Interventions will also promote HIV testing and counseling (HTC) and create demand for the uptake of HTC services by KP and OVC, increase access to HIV, STI and tuberculosis (TB) services in addition to other health care services, and support access to universal coverage of HIV treatment for all eligible PLHIV within KP and OVP.

The Lupus Research Institute (LRI) invites applications for financial support for idea-driven, novel research projects relevant to basic, translational or clinical investigation in lupus. Novel Research Grants provide early stage support for exceptionally creative and innovative approaches to major challenges in lupus research. Successful proposals will advance novel hypotheses and/or technologies that have the potential to stimulate new research directions and propel the field forward. Applications will be judged principally on novelty of the hypotheses, scientific quality, strength of approach, relevance to lupus, likelihood of success, and potential impact for those living with lupus. Rationale for the hypotheses proposed rather than amount of preliminary data will be emphasized. Continuations of long-term research projects are not appropriate for this submission. The program goals are to stimulate investigation of underexplored pathways and generate transformative discoveries in lupus that can drive the development of safer and more effective treatments. Investigations into the fundamental mechanisms of lupus and its complications, explorations of novel targets and pathways, and applications involving novel technologies and interdisciplinary approaches are particularly encouraged.

The Experimental Program to Stimulate Competitive Research (EPSCoR) is a program designed to fulfill the National Science Foundation's (NSF) mandate to promote scientific progress nationwide. The EPSCoR program is directed at jurisdictions that have historically received lesser amounts of NSF Research and Development (R&D) funding. Thirty-one jurisdictions including twenty-eight states, the Commonwealth of Puerto Rico, the U. S. Virgin Islands, and Guam currently are eligible to participate. Through this program, NSF establishes partnerships with government, higher education, and industry that are designed to effect lasting improvements in a state's or region's research infrastructure, R&D capacity and hence, its national R&D competitiveness.Research Infrastructure Improvement Program: Track-2 (RII Track-2) awards provide funds in the range of $1.5 to 2.0 million per year for up to 3 years to consortia of EPSCoR jurisdictions. The awards promote opportunities for collaborations among EPSCoR jurisdictions in all areas of science, engineering, and education supported by the National Science Foundation (NSF). RII Track-2 proposals must describe a clear, comprehensive, and integrated vision to drive discovery, and train a skilled workforce capable of solving science and engineering challenges of regional, thematic, and national relevance. Proposals should also include a strong rationale for the establishment of the consortium and clearly demonstrate that the consortium is well-positioned to produce results that cannot be obtained by any single partner working independently. The Science, Technology, Engineering, and Mathematics (STEM) research and education activities should broaden participation by different types of institutions, individuals, and sectors in the project.

The goal of a Bioengineering Research Partnership (BRP) is to drive the development and speed the adoption of promising tools and technologies that can address important biomedical problems for which insufficient or no solutions exist.  The use of engineering principles is encouraged to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need. A synergistic partnership between engineering and the life, physical, and computational sciences is also encouraged, where the unique skills of each discipline combine to enhance our understanding of life science processes or the practice of medicine. The purpose of this FOA is to encourage BRP applications that: 1) establish a robust engineering solution to a problem in biomedical research or the practice of medicine; 2) develop a strategic alliance of multidisciplinary partners based on a well-defined leadership plan; and 3) realize a specific endpoint within 5-10 years based on a detailed plan with a timeline and quantitative milestones.

The program goals are to stimulate investigation of underexplored pathways and initiate transformative discoveries in lupus that can drive the development of safer and more effective treatments. Investigations into the fundamental mechanisms of lupus and its complications, explorations of novel targets and pathways, and applications involving novel technologies and interdisciplinary approaches are particularly encouraged.

The Chan Zuckerberg Initiative (CZI) seeks to support up to 10 Imaging Scientists who will work at the interface of biology, microscopy hardware, and imaging software at imaging centers across the United States. "Imaging Scientists" might be engineers, physicists, mathematicians, computer scientists, or biologists who have focused on technology development in either microscopy or data analysis fields. The primary goal of the program is to increase interactions between biologists and technology experts. The Imaging Scientists will have expertise in microscopy hardware and/or imaging software. A successful "Imaging Program" will employ an Imaging Scientist who: a) works collaboratively with experimental biologists on projects at the imaging center; b) participates in courses that disseminate advanced microscopy methods and analysis; c) trains students and postdocs in imaging technology; d) participates in a network of CZI Imaging Scientists to identify needs and drive advances in the imaging field; e) attends twice-yearly CZI scientific workshops and meetings in imaging and adjacent biomedical areas. Each grant will fund salary and fringe benefits for an Imaging Scientist at the center, a modest travel and teaching budget, plus 15% indirect costs. The award period is three years plus an additional two years if the Imaging Program passes a review at year three.

The NSF 2026 Idea Machine is a competition to help set the U.S. agenda for fundamental research in science and engineering. Participants can earn prizes and receive public recognition by suggesting the pressing research questions that need to be answered in the coming decade, the next set of "Big Ideas" for future investment by the National Science Foundation (NSF). It's an opportunity for researchers, the public and other interested stakeholders to contribute to NSF's mission to support basic research and enable new discoveries that drive the U.S. economy, enhance national security and advance knowledge to sustain the country's global leadership in science and engineering.

mportant aspects of this award mechanism include: * Impact: Applications should articulate both the short- and long-term impact of the proposed research. Projects must address one or more of the FY19 SCIRP IIRA Focus Areas. * Relevance to Military Health: Projects should be relevant to spinal cord-injured military Service members, Veterans, and/or their family members and caregivers. Collaboration with military and VA researchers and clinicians is encouraged. * Preliminary Data: Observations that drive a research idea may be derived from laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to the mission of the SCIRP and support the proposed research project. IIRA applications may focus on any phase of research from basic through translational. Permitted research includes preclinical studies in animal models, research with human subjects, or human anatomical substances, as well as ancillary studies associated with an existing clinical trial. Applications including animal studies must include a clear justification for the animal model chosen including relevance to human SCI.

The NIGMS BTRR program has recently been evaluated and the final report is available on the NIGMS BTRR web page (https://publications.nigms.nih.gov/btrrs/searchresults.asp). Several important changes have been made to simplify and clarify the application and review process, and to improve the flexibility of individual Resources and the overall program. The program continues to focus on two goals: the development of enabling technologies, and sustainable access to those technologies for the research community. These goals are addressed through three components of each center: Technology Research and Development (TR&D), Driving Biomedical Projects (DBPs), and Community Engagement (CE).

The Energy, Power, Control, and Networks (EPCN) Program supports innovative research in modeling, optimization, learning, adaptation, and control of networked multi-agent systems, higher-level decision making, and dynamic resource allocation, as well as risk management in the presence of uncertainty, sub-system failures, and stochastic disturbances. EPCN also invests in novel machine learning algorithms and analysis, adaptive dynamic programming, brain-like networked architectures performing real-time learning, and neuromorphic engineering. EPCN's goal is to encourage research on emerging technologies and applications including energy, transportation, robotics, and biomedical devices & systems. EPCN also emphasizes electric power systems, including generation, transmission, storage, and integration of renewable energy sources into the grid; power electronics and drives; battery management systems; hybrid and electric vehicles; and understanding of the interplay of power systems with associated regulatory & economic structures and with consumer behavior.